Remdesivir India Sub-Licensing: Gilead Indicates Conditional Position For Subcontracting
Executive Summary
Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.
You may also be interested in...
Remdesivir Rivals Hit Indian Market
Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.
Hetero, Cipla's Remdesivirs Hit India Market, 'Surplus' Envisaged By August
Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.
Coronavirus Update: India Approves Remdesivir, Ex-Biogen Employee Charged
A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.